Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK3 | Q16288 | 11/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 10/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 10/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28690942 | 1.00 | NTRK3 (1.00) | NTRK3NTRK1NTRK2KDRCHEK1 | |
| SCHEMBL28700920 | 0.82 | NTRK3 (0.70) | NTRK3NTRK1NTRK2KDRCHEK1 | |
| SCHEMBL28700923 | 0.82 | NTRK3 (0.70) | NTRK3NTRK1NTRK2KDRCHEK1 | |
| SCHEMBL30792157 | 0.80 | NTRK3 (0.66) | NTRK3NTRK1NTRK2KDRCHEK1 | |
| SCHEMBL28933421 | 0.80 | NTRK1 (0.72) | NTRK3NTRK1NTRK2KDRCHEK1 | |
| SCHEMBL28706602 | 0.80 | NTRK1 (0.72) | NTRK3NTRK1NTRK2KDRCHEK1 | |
| SCHEMBL28686120 | 0.80 | NTRK3 (0.66) | NTRK3NTRK1NTRK2KDRCHEK1 | |
| SCHEMBL28933419 | 0.80 | NTRK1 (0.72) | NTRK3NTRK1NTRK2KDRCHEK1 | |
| SCHEMBL29855172 | 0.80 | NTRK3 (0.66) | NTRK3NTRK1NTRK2KDRCHEK1 | |
| SCHEMBL28706603 | 0.80 | NTRK1 (0.72) | NTRK3NTRK1NTRK2KDRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4056558-A1 | INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | Jinan University (CN) | 2022-09-14 | — | — | EP | disclosed |
| US-20220281821-A1 | INDAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS | JINAN UNIVERSITY (CN) | 2022-09-08 | — | — | US | disclosed |
| CN-114072387-A | Indazole compound and medicinal composition and application thereof | 暨南大学 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281821-A1 | INDAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS | TNK2, TNNI3K, CSNK1G3 | NTRK3 42/4885NTRK1 63/4885NTRK2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.